H.C. Wainwright analyst Swayampakula Ramakanth downgraded Surface Oncology (SURF) to Neutral from Buy with a $5 price target after the company announced that it has entered into an agreement to merge with Coherus BioSciences (CHRS) and be acquired in a stock-for-stock transaction for up to $65M.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SURF:
- Surface Oncology implements 50% workforce reduction
- Coherus to Acquire Surface Oncology
- Coherus Biosciences, Surface Oncology enter definitive merger agreement
- Surface Oncology (SURF) Q1 Earnings Cheat Sheet
- Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2023
Questions or Comments about the article? Write to editor@tipranks.com